TIGIT and laryngeal carcinoma: Cholangiocarcinoma and head and neck squamous cell carcinoma, including oral cancer, pharyngeal cancer and laryngeal cancer, exhibit an inhibitory immune microenvironment, in which TIGIT is positively expressed (117, 118), suggesting that targeting TIGIT may be with a promising application prospect.